rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer’s disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine

MLA

Yasunori Oda, et al. “RCBF and Cognitive Impairment Changes Assessed by SPECT and ADAS-Cog in Late-Onset Alzheimer’s Disease after 18 Months of Treatment with the Cholinesterase Inhibitors Donepezil or Galantamine.” Brain Imaging and Behavior, vol. 13, Dec. 2017, pp. 75–86. EBSCOhost, https://doi.org/10.1007/s11682-017-9803-y.

APA

Yasunori Oda, Koichi Sato, Toshiyuki Okubo, Yukihiko Shirayama, Michio Takahashi, Masaomi Iyo, & Kouhei Yoshino. (2017). rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer’s disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. Brain Imaging and Behavior, 13, 75–86. https://doi.org/10.1007/s11682-017-9803-y

Chicago

Yasunori Oda, Koichi Sato, Toshiyuki Okubo, Yukihiko Shirayama, Michio Takahashi, Masaomi Iyo, and Kouhei Yoshino. 2017. “RCBF and Cognitive Impairment Changes Assessed by SPECT and ADAS-Cog in Late-Onset Alzheimer’s Disease after 18 Months of Treatment with the Cholinesterase Inhibitors Donepezil or Galantamine.” Brain Imaging and Behavior 13 (December): 75–86. doi:10.1007/s11682-017-9803-y.